Ignite Creation Date:
2024-05-06 @ 4:05 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04865861
Status:
UNKNOWN
Last Update Posted:
2021-05-04
First Post:
2021-04-25
Brief Title:
The Characteristic of Airway Microbiome Profiling of COPD-bronchiectasis Overlap Patients and Its Association With Acute Exacerbation
Sponsor:
Guangzhou Medical University
Organization:
Guangzhou Medical University
Study Overview
Official Title:
The Characteristic of Airway Microbiome Profiling of Chronic Obstructive Pulmonary Disease-bronchiectasis Overlap Patients and Its Association With Acute Exacerbation
Status:
UNKNOWN
Status Verified Date:
2021-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The overlap between chronic obstructive pulmonary disease COPD and bronchiectasis is a neglected area of research and it is not covered by guidelines for clinical practice
COPD and bronchiectasis share common symptoms of cough with sputum production and susceptibility to recurrent exacerbations driven by new or persistent infection
Physiological criteria for the diagnosis of COPD and structural criteria for the diagnosis of bronchiectasis create the possibility for individual patients to fulfil both resulting conceptually in either co-diagnosis or an overlap syndrome between the two conditions The prevalence of this overlap will vary depending on the respective prevalence of COPD and bronchiectasis in the population under consideration
A recent study of 201 COPD patients with airway wall abnormalities typical of bronchiectasis confirmed an association with exacerbations and was predictive of mortality over 48 months A further single-centre study demonstrated a near three-fold increased mortality rate with patients with bronchiectasis and associated COPD having a 5-year mortality of 55 compared with 20 in those with bronchiectasis without COPD Airflow obstruction is perhaps best considered one marker of disease severity in bronchiectasis
Disease-associated exacerbations have a major effect on patient healthcare costs as well as quality of life due to increased lung damage and mortality risk Microorganisms such as Pseudomonas aeruginosa and to a lesser extent other Gram-negative and Gram-positive microorganisms identified in culture have been linked to disease progression poor clinical outcomes in bronchiectasis and driving airway neutrophil-mediated inflammation The microbiome has the potential to provide valuable information regarding disease phenotypeendotype treatment responses and targets for future therapy
COPD and bronchiectasis share common symptoms of cough with sputum production and susceptibility to recurrent exacerbations driven by new or persistent infection
Physiological criteria for the diagnosis of COPD and structural criteria for the diagnosis of bronchiectasis create the possibility for individual patients to fulfil both resulting conceptually in either co-diagnosis or an overlap syndrome between the two conditions The prevalence of this overlap will vary depending on the respective prevalence of COPD and bronchiectasis in the population under consideration
A recent study of 201 COPD patients with airway wall abnormalities typical of bronchiectasis confirmed an association with exacerbations and was predictive of mortality over 48 months A further single-centre study demonstrated a near three-fold increased mortality rate with patients with bronchiectasis and associated COPD having a 5-year mortality of 55 compared with 20 in those with bronchiectasis without COPD Airflow obstruction is perhaps best considered one marker of disease severity in bronchiectasis
Disease-associated exacerbations have a major effect on patient healthcare costs as well as quality of life due to increased lung damage and mortality risk Microorganisms such as Pseudomonas aeruginosa and to a lesser extent other Gram-negative and Gram-positive microorganisms identified in culture have been linked to disease progression poor clinical outcomes in bronchiectasis and driving airway neutrophil-mediated inflammation The microbiome has the potential to provide valuable information regarding disease phenotypeendotype treatment responses and targets for future therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None